{'fraction_non_alphanumeric': 0.04778453518679409, 'fraction_numerical': 0.043440486533449174, 'mean_word_length': 5.227027027027027, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Features, Prognosis, and Treatment Results of Patients With Scleritis From 2 Tertiary Eye Care Centers in Turkey

Purpose: To evaluate the spectrum of scleritis from 2 tertiary eye care centers in Turkey. Methods: Data from 114 patients with scleritis (82 female and 32 male; mean age, 48 ± 17.7 years; age range, 4-87 years; 47 diffuse, 49 nodular, 7 necrotizing, and 11 posterior) who had undergone treatment between 1995 and 2006 were recorded. Results: Mean follow-up duration was 16.9 months. Thirteen patients (12%) had bilateral ocular disease at presentation, and 21 patients (19%) developed bilateral ocular disease during follow-up. Decreased visual acuity was most common (60%) in posterior scleritis and least common (2%) in diffuse scleritis. Thirty-six patients (32%) had associated systemic disease, and in 13 patients (11%), scleritis was the presenting symptom of a systemic disease. Conclusions: Scleritis is a form of ocular inflammation frequently associated with systemic autoimmune disease and ocular complications. Close follow-up, systemic evaluation, and timely treatment are necessary in all patients with scleritis.